After several years of robust expansion, the leading branded pharma companies will see growth slow to just 1.3% from now to 2015, independent market analyst company Datamonitor said in a new report. The primary culprit: expirin…
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention — and lots of money…
Mergers, acquisitions and major restructurings made Big Pharma a much smaller and leaner sector, with some 54,000 jobs lost. At least that’s better than 2009’s 61,000 layoffs.
Continue reading Which Sector Lost…
This little-known biopharmaceutical outfit has signed not just one but seven partnership pacts with Big Pharmas to help develop some of its products. Micromet’s No. 1 appeal: It’s developing novel antibody-based drugs to treat …
A group of J&J shareholders has filed a complaint against the company, accusing directors of ignoring warnings signs pertaining to J&J’s massive product recalls and government probes of manufacturing defects and marketing pract…